Search results

Order by most recent / most popular / relevance

Results: 1-7 of 7

What did you say? $31 million awarded for infringement of hearing aid patent

McDermott Will & Emery
-
European Union
-
November 29 2012

In a case involving the alleged infringement of two patents related to hearing aids, one of which was found under judgment as a matter of law (JMOL) to not be infringed

Advocate General opinion on the interpretation of “first marketing authorisation” for Supplementary Protection Certificates

McDermott Will & Emery
-
European Union
-
June 7 2012

Advocate General Trstenjak (the AG) has rendered an opinion in a preliminary reference relating to Neurim Pharmaceuticals Ltd 1991 C-13011 that it should be possible to grant a Supplementary Protection Certificate (SPC) for a second medicinal product that comprises the same active ingredient as a medicinal product covered by a prior marketing authorisation (MA), if the scope of the basic patent protecting the second medicinal product does not extend to the earlier medicinal product

High Court of England and Wales has jurisdiction to try pan-European declaration of non-infringement action

McDermott Will & Emery
-
European Union, United Kingdom
-
January 9 2013

In Actavis Group HF v Eli Lilly and Company 2012 EWHC 3316 (Pat) the High Court of England and Wales has held that, in cases where there is no challenge

UK Supreme Court steps into line with Europe, but rejects U.S. approach

McDermott Will & Emery
-
European Union, United Kingdom, USA
-
November 30 2011

The UK’s highest court recently considered the provisions of the European Patent Convention (EPC) centering on the “susceptible of industrial application” requirement in the context of a patent describing a DNA sequence for a new protein, Neutrokine-α, which was a member of a group of similar proteins known as the TNF ligand superfamily

SPCs: is a simplistic system becoming too complicated?

McDermott Will & Emery
-
European Union
-
November 22 2010

Obtaining and enforcing Supplementary Protection Certificates (SPCs) for medicinal products in the European Union is a fertile ground for challenge and the law is still unclear in a number of key areas

Navigating the evolving regulation and commercialization of stem cell research

McDermott Will & Emery
-
European Union, USA
-
March 22 2012

Interested parties that can successfully navigate the evolving regulation of stem cell research stand to gain significant scientific and commercial advantage

Increased European patent protection following a landmark ruling on supplementary protection certificates

McDermott Will & Emery
-
European Union
-
August 30 2012

The Court of Justice of the European Union (CJEU) rendered judgment relating to a preliminary reference from the English Court of Appeal, holding that the existence of an earlier marketing authorization (MA) of a pharmaceutical product does not preclude the grant of a Supplementary Protection Certificate (SPC) for a different application of the same product

Search results

What did you say? $31 million awarded for infringement of hearing aid patent

Advocate General opinion on the interpretation of “first marketing authorisation” for Supplementary Protection Certificates

High Court of England and Wales has jurisdiction to try pan-European declaration of non-infringement action

UK Supreme Court steps into line with Europe, but rejects U.S. approach

SPCs: is a simplistic system becoming too complicated?

Navigating the evolving regulation and commercialization of stem cell research

Increased European patent protection following a landmark ruling on supplementary protection certificates

Current Search

Suggested Facets

Author

Jurisdiction

Workarea